Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thiomersal - Beech Tree Labs

Drug Profile

Thiomersal - Beech Tree Labs

Alternative Names: BTL-TML-COVID; BTL-TML-HSV; BTL-TML001; Thimerosal - Beech Tree Labs

Latest Information Update: 06 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beech Tree Labs
  • Class Antifungals; Antiseptics; Antivirals; Benzoates; Heavy metals; Organometallic compounds; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Protein biosynthesis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections; Herpes labialis
  • Phase I/II Herpes simplex virus infections; Influenza virus infections

Most Recent Events

  • 02 Jan 2023 Thiomersal is still in phase II trials for COVID-2019 infections (In adults, In the elderly) in USA (Sublingual) (NCT04522830)
  • 09 Mar 2021 Combined efficacy and adverse event data from two phase II trials in Herpes simplex virus infections released by Beech Tree Labs
  • 28 Feb 2021 Beech Tree Labs completes a phase II trial in COVID-2019 infections (In adults, In the elderly) in USA (Sublingual) (NCT04522830)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top